Has the Administrative Court’s Reversal of the IAA Decision in Pfizer Got It Right?

Daniela Ampollini, Oct 15, 2012

In my article, Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case, which appeared in the July (2) issue of the CPI Antitrust Chronicle, I discussed the reasons the Italian Antitrust Authority (“IAA”) found Pfizer liable of abuse of dominant position from a patent law perspective. I attempted to reconcile-without succeeding, in fact-the reasoning of the IAA with the meaning and function of the various patent law cat